Oncolytic Virus to Target MAGE-A3 for Solid Tumors is under clinical development by Turnstone Biologics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Oncolytic Virus to Target MAGE-A3 for Solid Tumors’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Oncolytic Virus to Target MAGE-A3 for Solid Tumors overview

Oncolytic virus (MG1-MAGEA3 program) is under development for the treatment of advanced solid tumors including breast cancer, esophageal cancer, gastro-esophageal junction (GEJ) carcinomas, gastric cancer, non-small cell lung adenocarcinoma. The vaccine candidate is administered through intravenous, intratumoral and intramuscular route. It is an attenuated, genetically-modified, oncolytic form of the Maraba virus. It constitutes of AdMA3 as a priming component and MG1MA3 as boosting component along with adenovirus vector. It was also under development for non squamous non-small cell lung cancer and squamous non-small cell lung cancer, metastatic melanoma and cutaneous squamous cell carcinoma.

Turnstone Biologics overview

Turnstone Biologics, a subsidiary of Turnstone Biologics Corp, is a clinical stage biotech company engaged in developing breakthrough cancer immunotherapies and drugs for the treatment of solid tumors. The company is headquartered in Ottawa, Ontario, Canada.

For a complete picture of Oncolytic Virus to Target MAGE-A3 for Solid Tumors’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.